Treatment News : Hep B Ups Death Risk Compared With Hep C, but Tenofovir Seems Protective - by David Evans

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Treatment News » March 2011

Most Popular Links
Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

20 Years Ago In POZ

More Treatment News

Click here for more news

Have news about HIV? Send press releases, news tips and other announcements to


March 11, 2011

Hep B Ups Death Risk Compared With Hep C, but Tenofovir Seems Protective

by David Evans

People with chronic hepatitis B virus (HBV) infection have twice the risk of dying from liver-related diseases as people with chronic hepatitis C virus (HCV)—including those also infected with HIV—according to a study presented Wednesday, March 2, at the 18th Conference on Retroviruses and Opportunistic Infections (CROI) in Boston. However, the introduction of tenofovir (found in Viread, Truvada and Atripla) as a common part of antiretroviral (ARV) therapy in 2003 has significantly reduced the risk of dying in people with HBV.

In the last decade, deaths from liver-related causes have eclipsed all other causes of death in people with HIV. The is largely due to the fact that roughly 10 percent of all people with HIV have chronic HBV infection and nearly a third of people with HIV are coinfected with HCV, and that both types of hepatitis are far more aggressive and deadly in people with HIV than in people who don’t have HIV.

Though overall death rates are well documented from both types of hepatitis, few studies have compared deaths from HBV with deaths from HCV in people coinfected with HIV. To explore this, Oluwaseun Falade-Nwulia, MD, MPH, of Johns Hopkins University in Baltimore, and her colleagues examined the medical records of 680 men who have sex with men (MSM) enrolled in the Multicenter AIDS Cohort Study (MACS), some of whom were HIV-positive and some of who were HIV-negative.

In the group, 337 people had chronic HBV infection, of whom 229 (68 percent) were coinfected with HIV. Roughly the same amount, 343 people, had chronic HCV infection, of whom 243 (71 percent) were also infected with HIV. The average age of participants with HBV was 32, and most were white. Meanwhile, the average age of those with HCV was 38, and the majority were black or Latino. There were 51 liver-related deaths during a seven-year follow-up period—36 in people with HBV and 15 in people with HCV. The majority were in people coinfected with hepatitis and HIV.

When Falade-Nwulia and her colleagues took into account a variety of factors that can affect liver health, such as age and alcohol and drug consumption, they found that people with HBV—whether coinfected with HIV or not—were more than twice as likely to die from liver-related deaths as people with HCV. However, most of the increased risk of death occurred between 1984 and 2002, before the use of tenofovir became widespread among people with HIV.

People with HBV who took tenofovir had a reduced risk of dying, the researchers noted, particularly in more recent years. Tenofovir is an approved medication to treat HBV, as are the ARV medications lamivudine (found in Epivir, Combivir, Trizivir and Epzicom) and emtricitabine (found in Emtriva, Truvada and Atripla). The researchers also found that liver-related deaths from HBV were about 93 percent lower in people with CD4 counts over 350 compared with people who had CD4s under 200.

The researchers summed up: “These data support the following in the HIV-infected population: screening for HB; immunization to protect against HBV infection; [and] treatment of HIV-HBV coinfected individuals with [an ARV regimen] that includes agents with potent anti-HBV activity.”

Search: Hepatitis B virus, hep B, HBV, hepatitis C virus, hep c, HCV, tenofovir, Viread, Truvada, Atripla, emtricitabine, emtriva, lamivudine, Epivir, Epzicom, Combivir, Trizivir, Oluwaseun Falade-Nwulia, liver, liver-related deaths

Scroll down to comment on this story.


(will display; 2-50 characters)


(will NOT display)


(will display; optional)

Comment (500 characters left):

(Note: The POZ team reviews all comments before they are posted. Please do not include either ":" or "@" in your comment. The opinions expressed by people providing comments are theirs alone. They do not necessarily reflect the opinions of Smart + Strong, which is not responsible for the accuracy of any of the information supplied by people providing comments.)

Comments require captcha.
Please enter this number for verification:

| Posting Rules

Show comments (0 total)

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Did you participate in an event for National Black HIV/AIDS Awareness Day 2016?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.